Email
Print
Angiosarcomas Treatment Market - Forecast(2024 - 2030)
Angiosarcomas Treatment Market Overview
Angiosarcomas Treatment Market Size is estimated to reach $970.4 million by 2027. Furthermore, it is poised to grow at a CAGR of 5.9% over the forecast period of 2022-2027. The growing prevalence of cancer in the world surges the growth of the angiosarcomas treatment market. According to a research study published by National Center for Biotechnology Information (NCBI), the survival rate of patients with angiosarcomas after liver transplantation the 12-month survival rate was 24% and the 24-month mortality rate was 100%. Owing to the high fatality rate of this disease various research organizations and key market players focus on the development of new innovative solutions for diagnosis and cure. For instance, in June 2022, the Food and Drug Administration granted accelerated approval to dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) for the treatment of adult and pediatric patients of 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. Such global demand for diagnosis and treatments such as pneumothorax treatment and the availability of new drugs and treatments drive the growth of the Angiosarcomas Treatment Industry over the forecast period 2022-2027.
Angiosarcomas Treatment Market Report Coverage
The report: “Angiosarcomas Treatment Market Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Angiosarcomas Treatment Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the best healthcare facilities and high funding for cancer research surge growth of the Angiosarcomas Treatment Market Size.
- The Angiosarcomas Treatment Market is predicted to increase owing to the growing geriatric population and the high prevalence of cancer around the world fueling the growth of the Angiosarcomas Treatment Market.
- However, the low availability of skilled healthcare workers may limit Angiosarcomas Treatment Industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Angiosarcomas Treatment Market Report.
Angiosarcomas Treatment Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Angiosarcomas Treatment Market Segment Analysis - By Treatment
Angiosarcomas Treatment Market based on treatment can be further
segmented into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy,
Immunotherapy, Pneumothorax Treatment, Immunohistochemistry and Others. The Surgery
segment held a dominant market share in the year 2021. This is owing to the
growing demand for biopsies to investigate types of cancer. It also helps in
proper diagnosis and treatment and play important role in various types of
cancer. According to cancer statistics, in 2021 by the American Cancer Society more
than 1 million biopsies performed in the United States. Owing to the global
prevalence of cancer the high demand for cancer surgeries is reported in the past
several years. According to a research paper published in the Lancet in January
2021, the indication for surgery of cancer will increase by 5 million
procedures (52%) between 2018 (90,65,000) and 2040 (1,38,21,000). Such growing
demand for cancer surgery drives the growth of the Angiosarcomas Treatment Market
Share.
However, Targeted therapy is estimated
to grow with the fastest CAGR of 6.3% over the forecast period 2022-2027.
This is owing to the attribute of targeted therapy which directly attacks cancer
cells, for example, Pazopanib blocks several cell enzymes called tyrosine
kinases that are important for cell growth and survival. It may be used to
treat certain advanced soft tissue sarcomas that have not responded to
chemotherapy. As chemotherapy offered a 30% success rate, targeted therapy
provides up to 80% success rate in some cases. Owing to such attributes of
targeted therapies more people adopt them. Such growing popularity of targeted
therapy due to its effectiveness fuels the growth of the Angiosarcomas Treatment
Market Share over the forecast period 2022-2027.
Angiosarcomas Treatment Market Segment Analysis - By End-users
Angiosarcomas Treatment Market based on the end users can be
further segmented into Hospitals & Clinics, Ambulatory Care Centers,
Specialised Clinics and Others. The hospital & clinics segment held a
dominant market share in the year 2021. This is owing to the growing admission
of cancer patients for diagnosis and treatment of cancer in hospitals. According
to a research paper published in Nature in November 2021, the study of
cancer patients visiting the emergency department (ED) from 2015 to 2019 in
Korea found that cancer-related ED visits accounted for 3.1% of all ED visits,
with 1.37 million cases over five years. Such a growing number of hospital
visits for cancer-related treatments such as pneumothorax treatment, immunohistochemistry
and others drive the growth of the Angiosarcomas Treatment Market Share.
However, Ambulatory Care Centers are estimated
to grow with the fastest CAGR of 6.1% over the forecast period 2022-2027
owing to the attributes of ambulatory care centers which provide patients with their
inpatient chemotherapy regimens and supportive care delivered in outpatient service. Where instead of spending the night in an inpatient bed,
patients stay at a nearby hotel or their home while receiving daily treatments
and supporting care in ambulatory care facilities. Owing to such facilities most peoples prefer ambulatory care centers rather than long stays at
hospitals. Such growing popularity of ambulatory care centers for the treatment of
various cancer fuels the growth of the Angiosarcomas Treatment Market share over
the forecast period 2022-2027.
Angiosarcomas Treatment Market Segment Analysis - By Geography
North America held a dominant market share of 34% in the year 2021. This is owing to developed healthcare infrastructure and favorable government policies for research and development of new drugs and treatments. According to National Cancer Institute, the budget for cancer research was increased by 99.3 million (1.6%) from 2020 to 2021. Also, the cases of angiosarcomas along with lymphedema and syncope are increasing in this region. In the United States, one case of angiosarcoma is diagnosed annually for every million persons. Approximately 1% to 2% of all sarcomas are angiosarcomas. Such growing cases of angiosarcomas with lymphedema and government support for research and development of new innovative drugs and treatments drive the growth of the Angiosarcomas Treatment Market Size in this region.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to the growing rate of the aging population and the high prevalence of cancer in the elderly population. As it is mostly found in people with age 70 and above and most of the Asia-pacific population is shifting towards old age driving the growth of the angiosarcomas market. According to the World Bank, the total population of south Asia with and above 65 years of age is 11,86,58,106 in 2021. Such a growing elderly population and high chances of cancer in the elderly population fuel growth of the Angiosarcomas Treatment Market Size over the forecast period 2022-2027.
Angiosarcomas Treatment Market Drivers
Growing Risk of Cancer in Geriatric Population Drive Market Growth.
The risk of cancer is high in the geriatric
population. According to Union for International Cancer Control (UICC), there
are currently over 703 million people worldwide above the age of 65 years,
representing 9.1% of the global population. Estimates suggest that this
proportion will rise to 15.9% (1.5 billion people) by 2050. Also, according to
GLOBOCAN data 2020, more than 50% of people who have cancer are 65 or older.
The estimated mortality of all types of cancer in people with age 70 and above
is 65,17,865 in 2030, as per UICC. Such growing prevalence and high mortality
rate owing to cancer-related disease in the geriatric population drive growth of
the Angiosarcomas Treatment Industry over the forecast period 2022-2027.
Growing Funding for Cancer Research Drive Angiosarcomas Treatment Market Growth.
The burden of cancer is increasing rapidly all over the globe. The
research published by JAMA Network in December 2021, found that 23.6 million
new global cancer cases in 2019 (17.2 million when excluding those with
nonmelanoma skin cancer), 10.0 million cancer deaths and an estimated 250
million disability-adjusted life years estimated to be owing to cancer. Such an
increasing global burden of cancer surges the need for better diagnostics &
treatment. Also, the rapid radiation therapy in breast cancer patients increases the risk of angiosarcomas cancer and drives the growth of the Angiosarcomas Treatment
Industry over the forecast period 2022-2027.
Angiosarcomas Treatment Market Challenge
Lack of Proper Diagnostic Facilities in Underdeveloped Countries is Hampering Market Growth
To minimize the severity of cancer
and decrease the mortality rate the availability of effective diagnostic
techniques plays an important role. In low and middle-income countries owing to lack
of proper infrastructure, low investment & funding, unavailability of skilled technicians, high cost of service and many other reasons proper
diagnostics is not possible. According to a research article published in Nature
in April 2022, there are currently a significant bias in cancer research toward
high-income countries (HICs), with little research being done that is important
to the needs of low- and middle-income countries (LMICs). However, by 2030, one
in eight individuals will receive a cancer diagnosis during their lifetime and
almost 75% of all cancer deaths will take place in LMICs. According to the
research paper published by the Lancet availability of diagnostics was 19% in
basic primary care facilities, 49% in advanced primary care facilities and 68%
in hospitals. Such low availability of diagnostics centers and high mortality
rate owing to lack of diagnostics may hamper the growth of the Angiosarcomas Treatment Industry growth over the
forecast period 2022-2027.
Angiosarcomas Treatment Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Angiosarcomas
Treatment Market. The top 10 companies in the Angiosarcomas Treatment Market are:
- F. Hoffmann La Roche Ltd.
- Novartis AG
- Bayer AG
- GlaxoSmithKline plc.
- Sanofi S.A.
- Amgen Inc.
- Merck & Co. Inc.
- AbbiVie Inc.
- Eli Lilly and Company
- Bausch Health
Recent Developments
- In April 2022, Novartis announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facilities to make, test and release commercial Zolgensma, as well as produce gene therapy products for current and future clinical trials.
- In October 2021, Amgen announced the successful completion of its previously announced acquisition of Teneobio, Inc. by cash payment of $900 million. The acquisition includes Teneobio's proprietary bispecific and multispecific antibody technologies, which complement Amgen's existing antibody capabilities and BiTE platform and will enable significant acceleration and efficiency in the discovery and development of new molecules.
- In October 2020, Roche announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older. The approval is primarily based on the results of 2 phase III studies, VIALE-A and VIALE-C.
Relevant Titles
Report Code: HCR 0078
Report Code: HCR 0195
Report Code: HCR 0194
For more Lifesciences and Healthcare Market reports, please click here